Vanda Pharmaceuticals Inc. VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancer The meeting provides a clear path towards filing ...

BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+ in prostate cancerThe meeting provides a clear path towards filing ...

A New York Oasis Lies in Path of City's Push to Build Housing By Liya Cui NEW YORK (Reuters) - A beloved public garden in lower Manhattan may soon become a casualty of New York's push to develop ...

Verastem’s Avutometinib and Defactinib combination therapy targets recurrent LGSOC and is expected to complete its rolling NDA by 2H2024 ... the FDA’s orphan drug designation for Avutometinib ...

Channel 13's Abel Garcia met with a local and a doctor to get your questions and concerns answered over new weight loss drugs LAS VEGAS (KTNV) — Chances are you or someone you know is taking one ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine. A final decision from ...